Insights into the Mechanism of Osteoporosis and the Available Treatment Options

被引:4
|
作者
Muniyasamy, Rajeshwari [1 ]
Manjubala, Inderchand [1 ]
机构
[1] Vellore Inst Technol, Sch Bio Sci & Technol, Vellore, Tamil Nadu, India
关键词
Primary and secondary osteoporosis; mechanism of osteoporosis; treatment options; anti-resorptive agents; anabolic therapy; bone mineral density; hormone replacement therapy; BONE-MINERAL DENSITY; INTRAVENOUS IBANDRONATE INJECTIONS; CLINICAL-PRACTICE GUIDELINES; POSTMENOPAUSAL WOMEN; STRONTIUM RANELATE; FRACTURE RISK; ZOLEDRONIC ACID; PREVENTION; TERIPARATIDE; ALENDRONATE;
D O I
10.2174/0113892010273783231027073117
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Osteoporosis, one of the most prevalent bone illnesses, majorly affects postmeno-pausal women and men over 50 years of age. Osteoporosis is associated with an increased susceptibility to fragility fractures and can result in persistent pain and significant impairment in affected individuals. The primary method for diagnosing osteoporosis involves the assessment of bone mineral density (BMD) through the utilisation of dual energy x-ray absorptiometry (DEXA). The integration of a fracture risk assessment algorithm with bone mineral density (BMD) has led to significant progress in the diagnosis of osteoporosis. Given that osteoporosis is a chronic condition and multiple factors play an important role in maintaining bone mass, comprehending its underlying mechanism is crucial for developing more effective pharma-ceutical interventions for the disease. The effective management of osteoporosis involves the utilisation of appropriate pharmacological agents in conjunction with suitable dietary interventions and lifestyle modifications. This review provides a comprehensive understanding of the types of osteoporosis and elucidates the currently available pharmacological treatment options and their related mechanism of action and usage.
引用
收藏
页码:1538 / 1551
页数:14
相关论文
共 50 条
  • [31] Treatment needs and current options for postmenopausal osteoporosis
    Gennari, Luigi
    Rotatori, Stefano
    Bianciardi, Simone
    Nuti, Ranuccio
    Merlotti, Daniela
    EXPERT OPINION ON PHARMACOTHERAPY, 2016, 17 (08) : 1141 - 1152
  • [32] Treatment options for glucocorticoid-induced osteoporosis
    Chiodini, Iacopo
    Merlotti, Daniela
    Falchetti, Alberto
    Gennari, Luigi
    EXPERT OPINION ON PHARMACOTHERAPY, 2020, 21 (06) : 721 - 732
  • [33] Current and emerging treatment options for postmenopausal osteoporosis
    Maxwell, Angie Eaton
    Maclayton, Darego
    Nguyen, Huong
    FORMULARY, 2008, 43 (05) : 166 - +
  • [34] New therapeutic options for osteoporosis prevention and treatment
    Lambing, CL
    JOURNAL OF WOMENS HEALTH & GENDER-BASED MEDICINE, 2003, 12 (04): : 416 - 416
  • [35] Currently available treatment options for neuroendocrine liver metastases
    Machairas, Nikolaos
    Daskalakis, Kosmas
    Felekouras, Evangelos
    Alexandraki, Krystallenia, I
    Kaltsas, Gregory
    Sotiropoulos, Georgios C.
    ANNALS OF GASTROENTEROLOGY, 2021, 34 (02): : 130 - +
  • [36] Safety of available treatment options for renal cell carcinoma
    Derosa, Lisa
    Albiges, Laurence
    Massard, Christophe
    Loriot, Yohann
    Fizazi, Karim
    Escudier, Bernard
    EXPERT OPINION ON DRUG SAFETY, 2016, 15 (08) : 1097 - 1106
  • [37] Alcohol addiction - the safety of available approved treatment options
    Antonelli, Mariangela
    Ferrulli, Anna
    Sestito, Luisa
    Vassallo, Gabriele A.
    Tarli, Claudia
    Mosoni, Carolina
    Rando, Maria M.
    Mirijello, Antonio
    Gasbarrini, Antonio
    Addolorato, Giovanni
    EXPERT OPINION ON DRUG SAFETY, 2018, 17 (02) : 169 - 177
  • [38] Urinary incontinence: Proper assessment and available treatment options
    Dmochowski, RR
    JOURNAL OF WOMENS HEALTH, 2005, 14 (10) : 906 - 916
  • [39] Prepubertal bipolar disorder: available pharmacological treatment options
    Masi, G
    EXPERT OPINION ON PHARMACOTHERAPY, 2005, 6 (04) : 547 - 560
  • [40] Pharmacoeconomics of Available Treatment Options for Metastatic Prostate Cancer
    Steven B. Zeliadt
    David F. Penson
    PharmacoEconomics, 2007, 25 : 309 - 327